Loading…
← CockpitCompetitor Analysis › H02.SI Haw Par Corporation LimitedOpen in the cockpit ↗

Haw Par Corporation LimitedH02.SICompetitor analysis, valuation and peers

Singapore · SGD·Health Care›Pharmaceuticals: Major

Singapore conglomerate known for the Tiger Balm healthcare brand, also holding large equity stakes in UOB and UOL Group.

≈ Singapore's Tiger Balm maker, also a large equity-investment holding companyMomentum weak 30
Mkt cap
$2.08B
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$1.79M
20-day average traded
Fwd P/E
11.9×
forward earnings
ROIC−WACC
-3.8 pp
WACC 5.2%
Hurdle
-12 pp
Req g minus delivered
Close · SGDS$12.27
1D-0.7%
1W-3.7%
1M-4.3%
3M-19.0%
6M-25.3%
YTD-21.8%
1Y-19.2%
ATR %1.8%
52w lowhigh32.8% off high

What Haw Par does

Singapore conglomerate known for the Tiger Balm healthcare brand, also holding large equity stakes in UOB and UOL Group.

Tiger Balm pain-relief products are made at its own factory in Singapore and sold through pharmacies and retailers across Asia and beyond. Alongside, it holds a large investment portfolio, chiefly UOB and UOL shares, which gives dividend income and portfolio gains independent of the consumer business.

In one line: Singapore's Tiger Balm maker, also a large equity-investment holding company.

Products and services

  • Tiger Balm healthcare/pain-relief products
  • Investment portfolio (UOB, UOL stakes)
  • Leisure/property assets

Customers

  • Consumers buying Tiger Balm and healthcare product

Where it sits in the supply chain

  • Consumer health & investment holding
  • Healthcare/pain-relief brand
  • Equity investment portfolio

What could go right

  • Tiger Balm brand demand growth in new markets
  • Dividend income from UOB/UOL equity stakes

What could go wrong

  • Consumer healthcare competitive pressure
  • Equity portfolio concentration risk

Moat: wide (brand, IP / patents). Tiger Balm is a globally recognized, century-old heritage brand with strong pricing power in its niche.

Headquarters: Singapore · Founded: 1926

Named competitors

Haw Par at a glance

Size Haw Par (H02.SI) is a Singapore Health Care company (Pharmaceuticals: Major) with a market value of $2.08B, the 47th largest of 184 Singapore companies the cockpit tracks. Shares closed at S$12.27 on 18 Nov 2026.

Performance Over six months the shares fell 25.3%, against +2.8% for the median peer and -4.6% for the Singapore market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 13.2% over the last twelve months (peer median +10.7%); the operating margin is 30.4% (peer median 14.7%).

Valuation It trades at 11.9× forward earnings against a peer median of 24.4× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.8 points below its cost of capital (5.2% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 102H02.SI 74
Six months, rebased to 100: Haw Par against the median of its 20 peers (local-currency closes).

Haw Par financials

Reported figures in SGD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueS$220MS$230MS$245MS$232MS$182M
Revenue growth—-6%+5%+27%—
Gross profitS$122MS$129MS$134MS$135MS$98.6M
EBITDAS$73.2MS$75.8MS$70.6MS$71.4MS$51.5M
Net incomeS$229MS$265MS$228MS$217MS$148M
Free cash flowS$225MS$269MS$234MS$209MS$129M
Capital expenditureS$2.40MS$2.12MS$3.46MS$7.77MS$19.7M
Total debtn/aS$44.7MS$36.8MS$28.5MS$29.2M

Quarterly statements and history in the cockpit →

Haw Par competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%688428214450600285603707603456300436009420ERIS600267600867APLLTDBHVNONESOURCEHRMY60020145400512603858SHILPAMEDALIVUSH02.SI6-month return →1-month return →
Up and to the right = strong over both horizons. Haw Par is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%25×50×75×688428214450600285603707603456ERISONESOURCEHRMY6002014540SHILPAMEDH02.SIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Haw Par is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%688428214450600285603707ERIS600267H02.SIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Haw Par is the large dot.

Haw Par competitors and peer comparison

Head to head with its named competitors (H02.SI vs JNJ vs HLN.L vs 4527.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Haw Par H02.SI$2.08B-25%-13%30%11.9×3.2%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Haleon HLN.L$39.6B0%+1%23%16.4×5.2%
Rohto Pharmaceutical 4527.T$3.87B+8%+7%12%16.5×-2.8%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%

How Haw Par compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Haw Par against its 20 peers (data as of 18 Nov 2026)
MeasureH02.SIPeer medianRank in peer set
1-month return-4.3%+2.2%8th lowest of 21
6-month return-25.3%+2.8%2nd lowest of 21
Distance from 52-week high-32.8%-23.5%6th lowest of 21
Revenue growth (TTM)-13.2%+10.7%lowest of 20
Operating margin30.4%14.7%4th highest of 19
Forward P/E11.9×24.4×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)3.2%1.1%6th most demanding of 15
Growth delivered (Del g)+15.7%+8.5%6th highest of 15
Hurdle (Req g minus delivered)-12.4 pp-4.7 pp7th least demanding of 15
ROIC minus cost of capital-3.8 pp+0.8 pp4th lowest of 19
EV / EBITDA25.3×15.4×3rd most expensive of 10
Net debt / EBITDA-11.3×1.1×least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%

Questions

Who are Haw Par's main competitors?
Named competitors: Johnson & Johnson (JNJ), Haleon (HLN.L), Hisamitsu Pharmaceutical (private or unlisted), Rohto Pharmaceutical (4527.T), Yunnan Baiyao (000538.SZ). The cockpit's measured peer set (industry) also includes InnoCare Pharma (688428.SS), PharmaResearch (214450.KS), Henan Lingrui Pharmaceutial (600285.SS), Nanjing King-friend Biochemical Pharmaceutical (603707.SS), Zhejiang Jiuzhou Pharmaceutical (603456.SS), Fujian Cosunter Pharmaceutical (300436.SZ).
Is Haw Par expensive compared with its peers?
On forward p/e it trades at 11.9× against a peer median of 24.4×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Haw Par stock performed?
Over six months to 18 Nov 2026 the shares returned -25.3% against +2.8% for the median peer; over one year -19.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.